Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.
Source: Wikipedia
Campaign Finance
$103,850 GivenFigures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.
-
Top Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
-
Republicans vs. Democrats
in dollars. "Other" includes 3rd parties and organizations without official party affiliation. -
State vs. Federal
in dollars -
Top PAC Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
Lobbying
$1,845,936 SpentFigures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying On Behalf of Boehringer Ingelheim Corp
-
Names of Lobbyists
-
Firm Hired Amount Venable LLP $90,000 Rubicon Advisors $90,000 Jennifer Bell & Partners $60,000 -
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Pharmacy,
- Alcohol & Drug Abuse,
- Copyright, Patent & Trademark,
- Medicare & Medicaid,
- Agriculture,
- Fed Budget & Appropriations,
- Taxes
-
Most Frequently Disclosed Bills
Bill No. Title S.2029 H.R.1706 Protecting Consumer Access to Generic Drugs Act of 2009 H.R.4213 Tax Extenders Act of 2009
Regulations
1 MentionsAll data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Boehringer Ingelheim Corp" in public comments on proposed federal regulations.
-
Mentions in Document Text
